CA3064785A1 - Epitopes in the rna recognition motif 1 (rrm1) of tdp-43 and misfolding-selective antibodies thereto - Google Patents

Epitopes in the rna recognition motif 1 (rrm1) of tdp-43 and misfolding-selective antibodies thereto Download PDF

Info

Publication number
CA3064785A1
CA3064785A1 CA3064785A CA3064785A CA3064785A1 CA 3064785 A1 CA3064785 A1 CA 3064785A1 CA 3064785 A CA3064785 A CA 3064785A CA 3064785 A CA3064785 A CA 3064785A CA 3064785 A1 CA3064785 A1 CA 3064785A1
Authority
CA
Canada
Prior art keywords
seq
antibody
amino acid
acid sequence
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3064785A
Other languages
English (en)
French (fr)
Inventor
Steven Samuel PLOTKIN
Neil R. Cashman
Xubiao PENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of CA3064785A1 publication Critical patent/CA3064785A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3064785A 2017-05-30 2018-05-30 Epitopes in the rna recognition motif 1 (rrm1) of tdp-43 and misfolding-selective antibodies thereto Pending CA3064785A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762512647P 2017-05-30 2017-05-30
US62/512,647 2017-05-30
US201762570582P 2017-10-10 2017-10-10
US62/570,582 2017-10-10
US201762595866P 2017-12-07 2017-12-07
US62/595,866 2017-12-07
PCT/CA2018/050634 WO2018218352A1 (en) 2017-05-30 2018-05-30 Epitopes in the rna recognition motif 1 (rrm1) of tdp-43 and misfolding-selective antibodies thereto

Publications (1)

Publication Number Publication Date
CA3064785A1 true CA3064785A1 (en) 2018-12-06

Family

ID=64454301

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3064785A Pending CA3064785A1 (en) 2017-05-30 2018-05-30 Epitopes in the rna recognition motif 1 (rrm1) of tdp-43 and misfolding-selective antibodies thereto

Country Status (5)

Country Link
US (2) US11214613B2 (enExample)
EP (1) EP3634987A4 (enExample)
JP (1) JP7761373B2 (enExample)
CA (1) CA3064785A1 (enExample)
WO (1) WO2018218352A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3137882A1 (en) * 2019-05-23 2020-11-26 Tamara SEREDENINA Anti-tdp-43 binding molecules and uses thereof
CN114174515A (zh) * 2019-05-27 2022-03-11 英属哥伦比亚大学 tau中的构象特异性表位、其抗体和其相关方法
EP4041308A1 (en) 2019-10-07 2022-08-17 University of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2023194565A1 (en) * 2022-04-08 2023-10-12 Ac Immune Sa Anti-tdp-43 binding molecules
WO2025035133A1 (en) * 2023-08-10 2025-02-13 Board Of Regents, The University Of Texas System Bmp-7 antibody compositions & methods for treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7386496A (en) 1995-10-02 1997-04-28 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The An epithelial protein and dna thereof for use in early cancer detection
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
CA2743361C (en) 2008-10-06 2021-05-25 Neil R. Cashman Methods and systems for predicting misfolded protein epitopes
GB0922435D0 (en) * 2009-12-22 2010-02-03 Ucb Pharma Sa Method
ES2883212T3 (es) * 2011-10-28 2021-12-07 Biogen Int Neuroscience Gmbh Moléculas de unión específica a TDP-43
US9428575B2 (en) * 2012-12-31 2016-08-30 Development Center For Biotechnology Anti-granulysin antibodies and methods of use thereof
WO2016053610A1 (en) * 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CA3004593A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Systems and methods for predicting misfolded protein epitopes by collective coordinate biasing
US20180125920A1 (en) * 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions

Also Published As

Publication number Publication date
WO2018218352A1 (en) 2018-12-06
EP3634987A1 (en) 2020-04-15
EP3634987A4 (en) 2021-03-03
JP2020522475A (ja) 2020-07-30
US11214613B2 (en) 2022-01-04
US20200165327A1 (en) 2020-05-28
JP7761373B2 (ja) 2025-10-28
US20220162293A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
US11214613B2 (en) Epitopes in the RNA recognition motif 1 (RRM1) of TDP-43 and misfolding-selective antibodies thereto
AU2022201737B2 (en) Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto
US11779629B2 (en) Compositions comprising cyclic peptides derived from an A-beta peptide
US12173055B2 (en) N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US11970522B2 (en) Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide
US20180346534A1 (en) C-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US20180326027A1 (en) Epitopes in amyloid beta and conformationally-selective antibodies thereto
US20220056118A1 (en) Antibodies to misfolded tdp-43 and methods of use
EP4143322A1 (en) Single chain antibodies and intrabodies to misfolded tdp-43 and methods of use
US20250346655A1 (en) Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof
CA3142040A1 (en) Conformation-specific epitopes in tau, antibodies thereto and methods related thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929